
Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cureAward last edited on: 5/2/2022
Sponsored Program
SBIRAwarding Agency
NIH : NIAIDTotal Award Amount
$300,000Award Phase
1Solicitation Topic Code
855Principal Investigator
Stacy W RemiszewskiCompany Information
Evrys Bio LLC (AKA: Forge Life Sciences LLC)
3805 Old Easton Road
Doylestown, PA 18902
Doylestown, PA 18902
(267) 893-6755 |
business@evrysbio.com |
www.forgelifescience.com |
Location: Single
Congr. District: 01
County: Bucks
Congr. District: 01
County: Bucks
Phase I
Contract Number: 1R44AI157725-01A1Start Date: 8/20/2021 Completed: 7/31/2022
Phase I year
2021Phase I Amount
$300,000Public Health Relevance Statement:
Chronic hepatitis B virus (HBV) infection can lead to cirrhosis of the liver, hepatocellular carcinoma or liver failure; current treatments control the disease but are rarely curative. The applicant has developed preliminary data suggesting that sirtuin-2 (SIRT2) inhibitors can potentially contribute to a cure for chronic HBV. The goal of this proposal is to advance these results to proof of principle in a mouse model of chronic HBV infection, followed by identification of a development candidate that can be advanced to IND status and clinical studies for treatment of chronic HBV infections.
Project Terms:
inhibitor/antagonist ; inhibitor ; Surface Antigens ; Cell Surface Antigens ; Immunologic Surface Markers ; Immunological Surface Markers ; Antiviral Agents ; Antiviral Drugs ; Antivirals ; anti-viral agents ; anti-viral drugs ; anti-virals ; Biological Assay ; Assay ; Bioassay ; Biologic Assays ; Biological Availability ; Bioavailability ; Biologic Availability ; Physiologic Availability ; Southern Blotting ; DNA blotting ; southern hybridization ; Pharmaceutical Chemistry ; Medicinal Chemistry ; Pharmaceutic Chemistry ; Clinical Research ; Clinical Study ; Crystallization ; Cytomegalovirus ; CMV ; HCMV ; Salivary Gland Viruses ; cytomegalovirus group ; DNA ; Deoxyribonucleic Acid ; DNA Viruses ; Pharmacotherapy ; Drug Therapy ; drug treatment ; Pharmaceutical Preparations ; Drugs ; Medication ; Pharmaceutic Preparations ; drug/agent ; Enzymes ; Enzyme Gene ; Family ; Genotype ; Goals ; Hepatitis B e Antigens ; HBeAg ; Hepatitis Be Antigens ; e Antigens ; Primary carcinoma of the liver cells ; Hepatocarcinoma ; Hepatocellular Carcinoma ; Hepatocellular cancer ; Hepatoma ; Liver Cells Carcinoma ; liver carcinoma ; Human ; Modern Man ; In Vitro ; Lead ; Pb element ; heavy metal Pb ; heavy metal lead ; Liver ; hepatic body system ; hepatic organ system ; Liver Cirrhosis ; Hepatic Cirrhosis ; Inbred BALB C Mice ; BALB C Mouse ; BALB/c ; Mus ; Mice ; Mice Mammals ; Murine ; Patients ; Plasma ; Blood Plasma ; Plasma Serum ; Reticuloendothelial System, Serum, Plasma ; Proteins ; RNA Viruses ; Testing ; Translations ; Virion ; Virus Particle ; Virus Diseases ; Viral Diseases ; viral infection ; virus infection ; virus-induced disease ; Virus Replication ; viral multiplication ; viral replication ; virus multiplication ; Virus ; Measures ; Liver Failure ; Hepatic Failure ; base ; improved ; Phase ; Series ; Hepatocyte ; Hepatic Cells ; Hepatic Parenchymal Cell ; Liver Cells ; Serum ; Blood Serum ; Individual ; Therapeutic ; programs ; Clinic ; extracellular ; chronic HBV infection ; chronic hepatitis B virus infection ; Chronic Hepatitis B ; Lytotoxicity ; cytotoxicity ; success ; Animal Models and Related Studies ; model of animal ; model organism ; Animal Model ; Structure ; Modeling ; response ; computational chemistry ; disease control ; disorder control ; Silent Mating Type Information Regulator 2-like Proteins ; Sir2-like Proteins ; Sirtuins ; Effectiveness ; Dose ; Data ; Dose-Limiting ; in vivo ; Development ; developmental ; design ; designing ; anti-hepatitis B ; HBV Genotype ; hepatitis B virus genotype ; Hepatitis B Therapy ; HBV therapy ; HBV treatment ; Hepatitis B Therapeutic ; Hepatitis B Treatment ; mouse model ; murine model ; prototype ; in vitro testing ; candidate selection ; phase 2 study ; phase II study ; Regimen ; screening ; pharmacodynamic biomarker ; pharmacodynamic marker ; small molecule therapeutics ; clinical translation ; Hepatitis B Virus ; HBV ; Homologous Serum Hepatitis Virus ;
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00